{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:41:17Z","timestamp":1793018477477,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010310","name":"E. Matilda Ziegler Foundation for the Blind","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010310","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007862","name":"California National Primate Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013884","name":"Macula Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.omtm.2020.01.002","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T20:44:58Z","timestamp":1579553098000},"page":"179-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":147,"special_numbering":"C","title":["Suprachoroidal and Subretinal Injections of AAV Using Transscleral Microneedles for Retinal Gene Delivery in Nonhuman Primates"],"prefix":"10.1016","volume":"16","author":[{"given":"Glenn","family":"Yiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook Hyun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris N.","family":"Mollhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uyen Tu","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Thomasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Taraborelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2020.01.002_bib1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/978-1-4614-3209-8_86","article-title":"Advances in AAV vector development for gene therapy in the retina","volume":"801","author":"Day","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.omtm.2020.01.002_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jgm.1126","article-title":"Novel AAV serotypes for improved ocular gene transfer","volume":"10","author":"Lebherz","year":"2008","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omtm.2020.01.002_bib3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/gt.2011.151","article-title":"Novel adeno-associated viral vectors for retinal gene therapy","volume":"19","author":"Vandenberghe","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2020.01.002_bib4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-associated virus serotypes: vector toolkit for human gene therapy","volume":"14","author":"Wu","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.01.002_bib5","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on Leber\u2019s congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2020.01.002_bib6","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber\u2019s congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2020.01.002_bib7","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2020.01.002_bib8","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","article-title":"Age-dependent effects of RPE65 gene therapy for Leber\u2019s congenital amaurosis: a phase 1 dose-escalation trial","volume":"374","author":"Maguire","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2020.01.002_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMc0903652","article-title":"Vision 1 year after gene therapy for Leber\u2019s congenital amaurosis","volume":"361","author":"Cideciyan","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2020.01.002_bib10","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2020.01.002_bib11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1089\/hum.2018.244","article-title":"Development of a molecularly stable gene therapy vector for the treatment of RPGR-associated X-linked retinitis pigmentosa","volume":"30","author":"Giacalone","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2020.01.002_bib12","doi-asserted-by":"crossref","first-page":"E8547","DOI":"10.1073\/pnas.1805055115","article-title":"Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector","volume":"115","author":"Cideciyan","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2020.01.002_bib13","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.ymthe.2017.05.004","article-title":"Optimization of retinal gene therapy for X-linked retinitis pigmentosa due to RPGR mutations","volume":"25","author":"Beltran","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.01.002_bib14","article-title":"Safety and toxicology of ocular gene therapy with recombinant AAV Vector rAAV.hCNGA3 in non-human primates","author":"Peters","year":"2019","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.omtm.2020.01.002_bib15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/humc.2017.125","article-title":"Safety and efficacy of AAV5 vectors expressing human or canine CNGB3 in CNGB3-mutant dogs","volume":"28","author":"Ye","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.omtm.2020.01.002_bib16","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ymthe.2018.05.025","article-title":"Retinal AAV8-RS1 gene therapy for X-linked retinoschisis: initial findings from a phase I\/IIa trial by intravitreal delivery","volume":"26","author":"Cukras","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.01.002_bib17","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1089\/hum.2015.142","article-title":"Preclinical dose-escalation study of intravitreal AAV-RS1 gene therapy in a mouse model of X-linked retinoschisis: dose-dependent expression and improved retinal structure and function","volume":"27","author":"Bush","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2020.01.002_bib18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymthe.2018.11.003","article-title":"Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration","volume":"27","author":"Grishanin","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.01.002_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ajo.2019.03.006","article-title":"Three-year follow-up of phase 1 and 2a rAAV.sFLT-1 subretinal gene therapy trials for exudative age-related macular degeneration","volume":"204","author":"Rakoczy","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2020.01.002_bib20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ebiom.2016.11.016","article-title":"Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration","volume":"14","author":"Constable","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.omtm.2020.01.002_bib21","first-page":"58","article-title":"Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye","volume":"29","author":"Medawar","year":"1948","journal-title":"Br. J. Exp. Pathol."},{"key":"10.1016\/j.omtm.2020.01.002_bib22","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/nri1224","article-title":"Ocular immune privilege: therapeutic opportunities from an experiment of nature","volume":"3","author":"Streilein","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omtm.2020.01.002_bib23","series-title":"Webvision: The Organization of the Retina and Visual System [Internet]","article-title":"Cellular remodeling in mammalian retina induced by retinal detachment","author":"Fisher","year":"2007"},{"key":"10.1016\/j.omtm.2020.01.002_bib24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2020.01.002_bib25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1586\/17512433.2014.890047","article-title":"Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis","volume":"7","author":"Todorich","year":"2014","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.omtm.2020.01.002_bib26","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/mt.2009.181","article-title":"Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous","volume":"17","author":"Dalkara","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.01.002_bib27","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1167\/iovs.18-24333","article-title":"Surgical removal of internal limiting membrane and layering of AAV vector on the retina under air enhances gene transfection in a nonhuman primate","volume":"59","author":"Teo","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2020.01.002_bib28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ymthe.2016.10.008","article-title":"Improved intravitreal AAV-mediated inner retinal gene transduction after surgical internal limiting membrane peeling in cynomolgus monkeys","volume":"25","author":"Takahashi","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.01.002_bib29","doi-asserted-by":"crossref","first-page":"189ra76","DOI":"10.1126\/scitranslmed.3005708","article-title":"In\u00a0vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2020.01.002_bib30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/mt.2010.234","article-title":"Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina","volume":"19","author":"Petrs-Silva","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.01.002_bib31","first-page":"1760","article-title":"Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential","volume":"14","author":"Li","year":"2008","journal-title":"Mol. Vis."},{"key":"10.1016\/j.omtm.2020.01.002_bib32","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1167\/iovs.17-22473","article-title":"Superior retinal gene transfer and biodistribution profile of subretinal versus intravitreal delivery of AAV8 in nonhuman primates","volume":"58","author":"Seitz","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2020.01.002_bib33","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1167\/iovs.17-22494","article-title":"Humoral immune response after intravitreal but not after subretinal AAV8 in primates and patients","volume":"59","author":"Reichel","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2020.01.002_bib34","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1016\/j.ymthe.2017.08.018","article-title":"AAV8 can induce innate and adaptive immune response in the primate eye","volume":"25","author":"Reichel","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.01.002_bib35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/OPTH.S89784","article-title":"The suprachoroidal space: from potential space to a space with potential","volume":"10","author":"Moisseiev","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.omtm.2020.01.002_bib36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/jamaophthalmol.2013.7288","article-title":"Characterization of the choroid-scleral junction and suprachoroidal layer in healthy individuals on enhanced-depth imaging optical coherence tomography","volume":"132","author":"Yiu","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.omtm.2020.01.002_bib37","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ajo.2017.11.020","article-title":"Choroidal changes after suprachoroidal injection of triamcinolone acetonide in eyes with macular edema secondary to retinal vein occlusion","volume":"186","author":"Willoughby","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2020.01.002_bib38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/IIO.0000000000000251","article-title":"Medical and surgical applications for the suprachoroidal space","volume":"59","author":"Emami-Naeini","year":"2019","journal-title":"Int. Ophthalmol. Clin."},{"key":"10.1016\/j.omtm.2020.01.002_bib39","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ajo.2006.05.045","article-title":"Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment","volume":"142","author":"Olsen","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2020.01.002_bib40","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal drug delivery to the back of the eye using hollow microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.omtm.2020.01.002_bib41","doi-asserted-by":"crossref","first-page":"7387","DOI":"10.1167\/iovs.14-14651","article-title":"Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles","volume":"55","author":"Kim","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2020.01.002_bib42","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.oret.2017.07.013","article-title":"Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the Tanzanite Study","volume":"2","author":"Campochiaro","year":"2018","journal-title":"Ophthalmol. Retina"},{"key":"10.1016\/j.omtm.2020.01.002_bib43","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1097\/IAE.0000000000002279","article-title":"Suprachoroidal injection of triamcinolone acetonide, CLS-TA, for macular edema due to noninfectious uveitis: a randomized, phase 2 study (DOGWOOD)","volume":"39","author":"Yeh","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.omtm.2020.01.002_bib44","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1167\/iovs.16-20070","article-title":"Effect of uveal melanocytes on choroidal morphology in rhesus macaques and humans on enhanced-depth imaging optical coherence tomography","volume":"57","author":"Yiu","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2020.01.002_bib45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.exer.2018.01.012","article-title":"Comparison of chorioretinal layers in rhesus macaques using spectral-domain optical coherence tomography and high-resolution histological sections","volume":"168","author":"Yiu","year":"2018","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.omtm.2020.01.002_bib46","doi-asserted-by":"crossref","first-page":"88ra54","DOI":"10.1126\/scitranslmed.3002103","article-title":"Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey","volume":"3","author":"Vandenberghe","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2020.01.002_bib47","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1089\/hgtb.2018.038","article-title":"Assessment of humoral, innate, and T-cell immune responses to adeno-associated virus vectors","volume":"29","author":"Calcedo","year":"2018","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.omtm.2020.01.002_bib48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/hum.2018.098","article-title":"Age-related seroprevalence of antibodies against AAV-LK03 in a UK population cohort","volume":"30","author":"Perocheau","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2020.01.002_bib49","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1038\/s41598-017-14715-z","article-title":"In\u00a0vivo multimodal imaging of drusenoid lesions in rhesus macaques","volume":"7","author":"Yiu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2020.01.002_bib50","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2020.01.002_bib51","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/hum.2016.111","article-title":"Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina","volume":"28","author":"Ramachandran","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2020.01.002_bib52","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.preteyeres.2009.12.002","article-title":"The multifunctional choroid","volume":"29","author":"Nickla","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.omtm.2020.01.002_bib53","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/mt.2010.258","article-title":"Preclinical safety evaluation of AAV2-sFLT01\u2014a gene therapy for age-related macular degeneration","volume":"19","author":"Maclachlan","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.01.002_bib54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/gt.2014.115","article-title":"Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates","volume":"22","author":"Kotterman","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2020.01.002_bib55","doi-asserted-by":"crossref","first-page":"e17140","DOI":"10.1371\/journal.pone.0017140","article-title":"Ab-externo AAV-mediated gene delivery to the suprachoroidal space using a 250 micron flexible microcatheter","volume":"6","author":"Peden","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2020.01.002_bib56","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1172\/JCI129085","article-title":"AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression","volume":"130","author":"Ding","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2020.01.002_bib57","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.exer.2016.10.011","article-title":"Distribution of particles, small molecules and polymeric formulation excipients in the suprachoroidal space after microneedle injection","volume":"153","author":"Chiang","year":"2016","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.omtm.2020.01.002_bib58","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1167\/iovs.16-20679","article-title":"Clearance kinetics and clearance routes of molecules from the suprachoroidal space after microneedle injection","volume":"58","author":"Chiang","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2020.01.002_bib59","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.oret.2018.03.008","article-title":"Suprachoroidal triamcinolone acetonide for diabetic macular edema: the HULK Trial","volume":"2","author":"Wykoff","year":"2018","journal-title":"Ophthalmol. Retina"},{"key":"10.1016\/j.omtm.2020.01.002_bib60","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-1-62703-080-9_25","article-title":"Adeno-associated viral vectors for gene therapy of inherited retinal degenerations","volume":"935","author":"Flannery","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtm.2020.01.002_bib61","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","article-title":"Standardization of vitreal inflammatory activity in intermediate and posterior uveitis","volume":"92","author":"Nussenblatt","year":"1985","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtm.2020.01.002_bib62","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-1-4939-7522-8_17","article-title":"Screening for neutralizing antibodies against natural and engineered AAV capsids in nonhuman primate retinas","volume":"1715","author":"Day","year":"2018","journal-title":"Methods Mol. Biol."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050120300139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050120300139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:22:16Z","timestamp":1762420936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050120300139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":62,"alternative-id":["S2329050120300139"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2020.01.002","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suprachoroidal and Subretinal Injections of AAV Using Transscleral Microneedles for Retinal Gene Delivery in Nonhuman Primates","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2020.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s).","name":"copyright","label":"Copyright"}]}}